News >

Pembrolizumab Improves PFS, ORR Versus Chemotherapy in Phase II Melanoma Study

Silas Inman @silasinman
Published: Sunday, Nov 16, 2014

Dr. Eric Rubin

Eric Rubin, MD

The PD-1 inhibitor pembrolizumab (Keytruda) significantly improved progression-free survival (PFS) by over 43% compared with chemotherapy as a treatment for patients with metastatic melanoma who were refractory to ipilimumab (Yervoy), according to findings from the KEYNOTE-002 study presented at the 2014 Society of Melanoma Research (SMR) Congress.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication